Remigromig demonstrated non-inferiority in mean change from baseline in best corrected visual acuity versus ranibizumab at one year in patients with diabetic macular ...

In the MEERKAT and SANDCAT studies, vamikibart demonstrated sustained improvements in vision and reductions in macular thickness in patients with UME at 52 weeks UME is ...

Protecting your eyesight over forty feels a lot like maintaining critical database infrastructure. When your visual acu ...

A prospective study of 46 patients shows that relaxing the 2022 international optic neuritis criteria and adding visual ...

Visual impairment poses a growing public health challenge in the United States, with 3.22 million people affected in some way, including 1.02 million individuals experiencing blindness as of 2015.

Researchers have found a possible way to stop abnormal signals in the retina that are linked to involuntary eye movements ...

Glaukos Corporation ( GKOS ), an ophthalmic pharmaceutical and medical technology company, announced positive topline results from a long-term Phase 3 extension study (GLK-202-03) evaluating the ...

Epioxa, an epithelium-on corneal cross-linking therapy for keratoconus, demonstrated positive outcomes in visual acuity, ...

After the liquidation of MSEC, new rules apply: we analyze the visual acuity indicators for establishing Group III disability ...

Atsena expects to complete enrollment in the third part of the Lighthouse study next year. (den-belitsky/iStock/ Plus) Atsena Therapeutics has reported evidence of efficacy in a clinical trial of an ...

ATSN-201 demonstrated structural and functional benefit in Parts A and B, including microperimetry improvements exceeding the level the FDA has ...